High expression of MAGE-A9 correlates with unfavorable survival in HCC

Results of researches from C S Monast and M J Lazzara highlight numerous other considerations that determine biochemical efficacy beyond those reflected by equilibrium affinities. By integrating these considerations, their model also predicts minimum therapeutic combination concentrations to maximally reduce receptor phosphorylation.

Their finding that the abilities of cetuximab and gefitinib to antagonize EGFR phosphorylation are determined by processes beyond those describing equilibrium drug binding motivates new consideration of optimal design strategies for EGFR-targeted therapeutics. To the extent that EGFR phosphorylation level correlates with clinical efficacy, these results also identify possible factors that could underlie the differential effectiveness of the therapeutics among patients

The identification ofEgfr dephosphorylation kinetics as a key determinant of therapeutic biochemical efficacy is intriguing given that the activities of protein tyrosine phosphatases that regulate EGFR are altered in certain cancer settings.

Their results also predict IC50 dependence on the rates of drug and ligand association and dissociation, even for constant affinities. Their prediction that slowing EGFR gefitinib binding and dissociation cycling decreases IC50 is consistent with the observation that slower erlotinib cycling promotes growth inhibition of lung and brain cancer cells.

Research from Xuefeng Gu and Maoying Fu showed that High expression of MAGE-A9 correlates with unfavorable survival in HCC. They concluded for the first time that MAGE-A9 can be recognized as a prognostic factor in HCC and that targeting MAGE-A9 may provide apromising therapeutic strategy for HCC treatment. Further studies that included more clinical samples of HCC are necessary to confirm our findings and to elucidate the possible mechanisms of MAGE-A9 characteristics in HCC.

In this study, they first investigated MAGE-A9mRNA expression in cell lines by RT-PCR. The results showed elevated Mage-A9 expression in four HCC cell lines compared to non-cancerous cell lines. Subsequently, the expression of MAGE-A9 mRNA in fresh

HCC tissues and matched non-cancerous tissues was evaluated by qPCR.

For survival analysis, Cox proportional hazards regression models,in which the effect of covariates is to multiply the hazard function by a function of the explanatory covariates, have achieved widespread application in the analysis of time-to-event data, with censoring and covariates. Their research team also constructed an anti-MAGE-A1 immunotoxin and verified its anti-tumor effectiveness. Considering the oncogenic role of MAGE-A9 in cancer, the application of treatment targeting MAGE-A9 is anticipated, and a fully human anti-MAGE-A9 antibody is currently being generated by their research group.

Numerologist Warda is hooked on OG-L002 fishing, collecting. And lastly her encouragement comes from socializing along with her companions.